Literature DB >> 8068669

Differential interactions of camptothecin lactone and carboxylate forms with human blood components.

Z Mi1, T G Burke.   

Abstract

The intrinsic fluorescent emissions from the lactone and carboxylate forms of camptothecin have been exploited in order to elucidate their markedly different interactions with the various components of human blood. In phosphate-buffered saline (PBS) at pH 7.4, human serum albumin (HSA) preferentially binds the carboxylate form with a 150-fold higher affinity than the lactone form; these interactions result in camptothecin opening more rapidly and completely in the presence of HSA than in the protein's absence [Burke, T.G., & Mi, Z. (1993) Anal. Biochem. 212, 285-287]. In human plasma, at pH 7.4 and 37 degrees C, we have observed camptothecin lactone to open rapidly and fully to the carboxylate form (t1/2 = 11 min; % lactone at equilibrium, 0.2%). Substitution of a 10-hydroxy moiety into the camptothecin fluorophore makes the agent's emission spectrum highly sensitive to microenvironment polarity; we have observed pronounced blue shifting (from 530 to 430 nm) in the emission spectra of the hydroxy-substituted carboxylate both upon HSA association as well as upon drug dissolution in organic solvents of low dielectric strength. Hence, it appears that camptothecin carboxylate's fluorophore locates in a hydrophobic binding pocket in native HSA. Ionic interactions also appear to strongly affect binding between camptothecin carboxylate and the HSA binding pocket, since a 6-fold increase in solution salt concentration diminished camptothecin carboxylate binding by 10-fold. Our findings that HSA denaturation abolishes high-affinity binding indicate that interactions of the carboxylate drug form are specific for the native HSA conformation. Interestingly, high-affinity binding of the carboxylate appeared not to occur in the presence of other blood proteins, such as gamma-globulin, alpha 1-acid glycoprotein, fibrinogen, and the oxy and deoxy forms of hemoglobin. In whole blood versus plasma, camptothecin was found to display enhanced stability (t1/2 value of 22 min and a lactone concentration at equilibrium value of 5.3%). The enhanced stability of camptothecin in human blood was found to be due to drug associations with the lipid bilayers of red blood cells. Camptothecin lactone partitions into the lipid bilayers of erythrocytes, with the drug locating in a hydrophobic environment protected from hydrolysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8068669     DOI: 10.1021/bi00200a013

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  36 in total

Review 1.  Camptothecin delivery methods.

Authors:  A Hatefi; B Amsden
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 2.  Role of red blood cells in pharmacokinetics of chemotherapeutic agents.

Authors:  Dirk Schrijvers
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Anticancer Camptothecin-N-Poly(lactic acid) Nanoconjugates with Facile Hydrolysable Linker.

Authors:  Qian Yin; Rong Tong; Lichen Yin; Timothy M Fan; Jianjun Cheng
Journal:  Polym Chem       Date:  2014       Impact factor: 5.582

4.  Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.

Authors:  Katherine E Peterson; Maris A Cinelli; Andrew E Morrell; Akhil Mehta; Thomas S Dexheimer; Keli Agama; Smitha Antony; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-06-28       Impact factor: 7.446

5.  Amphiphilic block co-polyesters bearing pendant cyclic ketal groups as nanocarriers for controlled release of camptothecin.

Authors:  Xiaoying Wang; Lisa A Gurski; Sheng Zhong; Xian Xu; Darrin J Pochan; Mary C Farach-Carson; Xinqiao Jia
Journal:  J Biomater Sci Polym Ed       Date:  2011       Impact factor: 3.517

6.  Layer-by-layer nanoencapsulation of camptothecin with improved activity.

Authors:  Gaurav Parekh; Pravin Pattekari; Chaitanya Joshi; Tatsiana Shutava; Mark DeCoster; Tatyana Levchenko; Vladimir Torchilin; Yuri Lvov
Journal:  Int J Pharm       Date:  2014-02-06       Impact factor: 5.875

Review 7.  Topoisomerases as anticancer targets.

Authors:  Justine L Delgado; Chao-Ming Hsieh; Nei-Li Chan; Hiroshi Hiasa
Journal:  Biochem J       Date:  2018-01-23       Impact factor: 3.857

8.  Controlled synthesis of camptothecin-polylactide conjugates and nanoconjugates.

Authors:  Rong Tong; Jianjun Cheng
Journal:  Bioconjug Chem       Date:  2010-01       Impact factor: 4.774

9.  Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity.

Authors:  Rupa R Sawant; Rishikesh M Sawant; Vladimir P Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2008-04-29       Impact factor: 5.571

10.  Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase I poisons.

Authors:  Maris A Cinelli; P V Narasimha Reddy; Peng-Cheng Lv; Jian-Hua Liang; Lian Chen; Keli Agama; Yves Pommier; Richard B van Breemen; Mark Cushman
Journal:  J Med Chem       Date:  2012-12-07       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.